• Positive safety of first cohort in Progenza trial

    Positive safety of first cohort in Progenza trial for knee osteoarthritis

    Jan 2016: Regeneus announced the completion of a review of safety from the first cohort of patients in the STEP trial, the first clinical trial of Progenza. The review of the safety data identified no safety concerns.

    More »

  • Patent granted for cancer vaccine technology

    Dec 2015: Regeneus has been granted a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in human and animals

    More »

  • High secreting cell identification and selection

    Breakthrough technology for high potency stem cells opens door for next generation cell therapies

    Nov 2015: Regeneus secures exclusive commercial rights to a breakthrough cell identification and selection technology developed by researchers at the Centre for Nanoscale Biophotonics at Macquarie University.

    More »

  • Positive results on early orthopaedic developmental disease in thoroughbreds

    Stem cells have positive results on early orthopaedic developmental disease in Yearling Thoroughbreds

    Nov 2015: Interim trial results showing that Regeneus' "off-the-shelf" stem cell therapy, CryoShot Equine, has positive results on early orthopaedic developmental disease in Yearling Thoroughbreds were presented by leading equine surgeon and principal investigator, Chris O'Sullivan.

    More »

Welcome to Regeneus

Regeneus Ltd (ASX: RGS) is an Australian clinical-stage regenerative medicine company developing a patented portfolio of cell therapies to address significant unmet medical needs in the human and animal health markets with a focus on musculoskeletal disease, oncology and dermatology.

Our technology platform includes 3 major platforms across both our human and animal health businesses:

  • Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases;
  • Human and animal immunotherapy personalised cancer vaccine for the treatment of a wide variety of cancers; and,
  • Stem cell secretions (cell free supernatant) – CFS technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments.

Regeneus’ strategy is to continue to develop innovative technologies partnering with larger companies with commercialisation capabilities to develop and market the products.

Product Pipelines

Regeneus Ltd Human Health Product Pipeline

Regeneus Ltd Veterinary Product Pipeline